相关实验视频

Updated: Feb 28, 2026

Ultrasonographic Evaluation of Breast Cancer-related Lymphedema

Ultrasonographic Evaluation of Breast Cancer-related Lymphedema

Published on: January 12, 2017

怀孕第一个和第三个三个月之间的乳房大小差异以及女性体型,皮下脂肪组织和生物化学参数的变化

Janina Tutkuviene¹, Simona Gervickaite², Jonas Drasutis²

¹Department of Anatomy, Histology and Anthropology, Faculty of Medicine, Vilnius University, M.K. Ciurlionio Str. 21/27, Vilnius, LT-03101, Lithuania. janina.tutkuviene@mf.vu.lt.

Scientific reports

|February 26, 2026

概括

怀孕显著改变了乳房体积和身体组成. 乳房大小的变化与身体脂肪和胆固醇水平相关,特别是在瘦身,乳房小的女性中.

科学领域:

身体生理学身体生理学
生物化学生化学
人类测量学人类测量学.

背景情况:

怀孕期间乳房的变化是显著的,但研究不足.
怀孕会引起女性的全身生理变化.
有限的文献涉及怀孕期间乳房体积变化.

研究的目的:

为了分析怀孕期间乳房体积的变化.
为了将乳房体积与身体大小和皮下脂肪相关联.
为了研究乳房体积和生化参数之间的关系.

主要方法:

在第一和第三季度对83名女性进行了纵向研究.
乳房体积用克莱默和德雷克斯勒公式计算.
评估身体尺寸,皮肤和胆固醇水平.

主要成果:

观察到显著的乳房体积变化 (第10周:544-3500厘米;第35周:689-3730厘米).
乳房体积类别与身体脂肪类别不一致 (35-67%).
最大的身体参数变化发生在瘦身,乳房小的女性中.
高密度脂蛋白胆固醇的增加在中大乳房妇女中观察到.
怀孕早期较高的低密度脂蛋白胆固醇与较大的乳房有关.

结论:

乳房体积在怀孕期间表现出相当大的变化,独立于整体体脂肪百分比.
身体成分和生化标志物,如胆固醇,显示出与怀孕期间乳腺大小的明显关联.
需要进一步的研究,以了解这些变化对母亲和胎儿健康的影响.

关键词:

生物化学参数生物化学参数身体大小身体尺寸乳房的体积乳房的体积怀孕怀孕怀孕怀孕皮下脂肪组织皮下脂肪组织

更多相关视频

Changes in Mammary Gland Morphology and Breast Cancer Risk in Rats

Changes in Mammary Gland Morphology and Breast Cancer Risk in Rats

Published on: October 16, 2010

Tracking the Mammary Architectural Features and Detecting Breast Cancer with Magnetic Resonance Diffusion Tensor Imaging

Tracking the Mammary Architectural Features and Detecting Breast Cancer with Magnetic Resonance Diffusion Tensor Imaging

Published on: December 15, 2014

相关概念视频

Signs of Puberty

Signs of Puberty

Puberty is a critical phase, typically beginning between the ages of 8 and 13 in girls and 9 and 14 in boys, though timing can vary based on genetics, environmental factors, and overall health. This period is characterized by the development of secondary sexual characteristics and the attainment of reproductive potential. Endocrine changes underpin puberty, with hormonal surges of Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH) instigated by Gonadotropin-Releasing Hormone (GnRH)...

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...